Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 3Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Kidney Neoplasms 1Castrate-resistant Prostate Cancer 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Has results × dactolisib × Clear all
NCT01717898 2018-03-27

A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

University of California, San Francisco

Phase 1/2 Terminated
6 enrolled 5 charts
Genitourinary

Castrate-resistant Prostate Cancer

NCT01628913 2016-04-07

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Novartis

Phase 2 Terminated
62 enrolled 7 charts
EndocrineNET

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01453595 2016-02-29

BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Terminated
10 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡